Publications by authors named "O A Vozdvizhenskaya"
Article Synopsis
- Modern antiviral drugs mainly target viral DNA polymerase to control HSV-1 infections.
- A new drug, LAS-131, showed promising results when combined with existing antivirals, significantly enhancing their effectiveness and allowing for lower dosages to inhibit the virus, potentially improving treatment options for herpes infections.
Herpes simplex virus type 1 (HSV-1) is an extremely widespread pathogen characterized by recurrent infections. HSV-1 most commonly causes painful blisters or sores around the mouth or on the genitals, but it can also cause keratitis or, rarely, encephalitis. First-line and second-line antiviral drugs used to treat HSV infections, acyclovir and related compounds, as well as foscarnet and cidofovir, selectively inhibit herpesvirus DNA polymerase (DNA-pol).
View Article and Find Full Text PDFArticle Synopsis
- Testing various derivatives of a specific compound demonstrated significant cytotoxic activity against several cancer cell lines, especially for types like 4T1 and HepG2.
- The research revealed that the effective compounds must include both a difluorobenzoxazine fragment and a purine residue connected by a specific length linker.
- Further studies indicated that the most promising compound inhibits DNA biosynthesis, suggesting potential for developing new antitumor agents based on the identified purine conjugates.
Introduction: Herpes simplex viruses type 1 (HSV-1) are extremely widespread throughout the world and, similar to other herpesviruses, establish lifelong persistent infection in the host. Reactivating sporadically, HSV-1 elicits recurrences in both immunocompetent and immunocompromised individuals and can cause serious diseases (blindness, encephalitis, generalized infections). The currently available antiherpetic drugs that aimed mainly at suppressing replication of viral DNA are not always effective enough, for example, due to the development of drug resistance.
View Article and Find Full Text PDF